CRISPR Therapeutics AG
CRSP- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001674416
In the last 90 days, CRISPR Therapeutics AG insiders filed 0 open-market purchases and 2 sales; 525 institutions reported holding it in 13F filings for Q2 2026, worth $4.16B in total; ARK Invest is the only superinvestor holding it.
Q2 2025 vs. Q1 2025
How the institutions holding CRISPR Therapeutics AG changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 398 | 4 | 435 | +41 |
| Shares | 64.7M | 1.91K | 72.4M | +7.70M (+11.9%) |
| Value | $2.20B | $65.1K | $3.52B | +$1.32B (+59.7%) |
4 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (101)
Institutions that held CRISPR Therapeutics AG at the end of Q2 2025 but not at the end of Q1 2025.
Showing the largest 100 of 101 by value.
Sold out (60)
Institutions that held CRISPR Therapeutics AG at the end of Q1 2025 and filed for Q2 2025 without it.
Not filed for Q2 2025 yet (4)
Institutions that held CRISPR Therapeutics AG at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Credit Agricole S A | 1,300 | $44.2K |
| Sandy Spring Bank | 582 | $19.8K |
| Lindbrook Capital, LLC | 26 | $885 |
| Spectrum Wealth Counsel, LLC | 4 | $137 |